About Lipoyl synthase, mitochondrial
Lipoyl synthase, mitochondrial (LIAS) is a protein
from Homo sapiens identified by UniProt accession
O43766, 372 residues long.
MolForge cross-references it against 0 known binders and
137 disease associations.
Target properties
| Protein name | Lipoyl synthase, mitochondrial |
|---|
| UniProt accession | O43766 |
|---|
| Gene | LIAS |
|---|
| Organism | Homo sapiens |
|---|
| Length | 372 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (137)
Diseases linked to this target (Open Targets).
- lipoic acid synthetase deficiency · score 0.77
- neurodegenerative disease · score 0.34
- genetic disorder · score 0.19
- cholelithiasis · score 0.10
- low density lipoprotein cholesterol measurement · score 0.09
- breast cancer · score 0.08
- esophageal squamous cell carcinoma · score 0.05
- hemorrhoid · score 0.05
- cystic fibrosis · score 0.04
- cancer · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O43766-F1 | alphafold | PREDICTED | 81.16 | — |
Amino-acid sequence (372 residues)
MSLRCGDAAR TLGPRVFGRY FCSPVRPLSS LPDKKKELLQ NGPDLQDFVS GDLADRSTWD EYKGNLKRQK GERLRLPPWL KTEIPMGKNY NKLKNTLRNL NLHTVCEEAR CPNIGECWGG GEYATATATI MLMGDTCTRG CRFCSVKTAR NPPPLDASEP YNTAKAIAEW GLDYVVLTSV DRDDMPDGGA EHIAKTVSYL KERNPKILVE CLTPDFRGDL KAIEKVALSG LDVYAHNVET VPELQSKVRD PRANFDQSLR VLKHAKKVQP DVISKTSIML GLGENDEQVY ATMKALREAD VDCLTLGQYM QPTRRHLKVE EYITPEKFKY WEKVGNELGF HYTASGPLVR SSYKAGEFFL KNLVAKRKTK DL
Explore Lipoyl synthase, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets